CCTC NATCO TOP Exam Questions and CORRECT Answers Antilymphocyte monoclonal antibodies ✔✔✔ Alemtuzamab(Campath1 -H) against CD 52 lymphocyte (both T and B cells),anti -CD20 antibodies Antilymphocyte monoclonal antibodies ✔✔✔ Rituxamib(rituxan) is a monoclonal antibody that depletes CD20 positive B cells monoclonal antibody ✔✔✔ Eculizumab (Solaris) directed against the C5 fragment in the complement cascade Interleukinn -2 (IL -2) receptor antibodies ✔✔✔ Basiliximabc(Simulect) may be used off - label for induction and antibody - mediated rejection Desensitization agents ✔✔✔ Plasmapheresis and IVIG Plasmapheresis (plasma exchange) ✔✔✔ Always done prior to the administration of IVIG or antibody therapy because plasmapheresis removes IVIG and other monoclonal antibodies during plasma exchange. IVIG ✔✔✔ Alemtuzumab (Campath) monoclonal antibody against C D52 lymphocyte (both T and B cells), anti CD20 antibodies Rituximab (Rituxan) ✔✔✔ Monoclonal antibody that depletes CD 20 positive B cells Eculizumab (Soliris) ✔✔✔ Monoclonal antibody directed against the C5 fragment in the complement cascade Used for dese nsitization and top of AMR Interleukin -2 (IL -2) is used as adjuvant therapy for renal cell carcinoma ✔✔✔ Basiliximab (Simulect) Induction therapy ✔✔✔ Used immediate post transplant to neutralize the intimacy robust T cell mediated immune response. Four ty pes of agents used for induction therapy treatment of acute rejection ✔✔✔ Polyclonal antibodies Monoclonal antibodies Interleukin -2 (IL -2)) receptor antibodies High dose glucocorticoids Use of polyclonal antibodies ✔✔✔ Helps to prevent early post transplan t ischemia -
repercussion injury. Patient may need to be treated with anti infective prophylaxis after use of polyclonal therapy ✔✔✔ Nystatin Acyclovir (Zovirax). 400 mg po q 12 hrs Valganciclovir (Valcyte) 900 mg po daily Trimethoprim/ sulfamethoxazole (Ba ctrim) double strength 1 tablet once daily, three times a week monoclonal antibodies ✔✔✔ Alemtuzumab (Campath) Approved by FDA for treatingrefactory B cellchronic lymphocytic leukemia and multiple sclerosis Used as off label for induction therapy in solid organ transplant Alemtuzumab (Campath) ✔✔✔ Black box warning : Increases risk of hematologic toxicities, infusion reactions, infection, and opportunistic infections Interleukin2 (IL -2) ✔✔✔ Basiliximab (Simulect) currently approved for induction therapy to prevent rejection in who have low to moderate risk of rejection Calcineurin inhibitors CNI ✔✔✔ Cyclosporine and tacrolimus
repercussion injury. Patient may need to be treated with anti infective prophylaxis after use of polyclonal therapy ✔✔✔ Nystatin Acyclovir (Zovirax). 400 mg po q 12 hrs Valganciclovir (Valcyte) 900 mg po daily Trimethoprim/ sulfamethoxazole (Ba ctrim) double strength 1 tablet once daily, three times a week monoclonal antibodies ✔✔✔ Alemtuzumab (Campath) Approved by FDA for treatingrefactory B cellchronic lymphocytic leukemia and multiple sclerosis Used as off label for induction therapy in solid organ transplant Alemtuzumab (Campath) ✔✔✔ Black box warning : Increases risk of hematologic toxicities, infusion reactions, infection, and opportunistic infections Interleukin2 (IL -2) ✔✔✔ Basiliximab (Simulect) currently approved for induction therapy to prevent rejection in who have low to moderate risk of rejection Calcineurin inhibitors CNI ✔✔✔ Cyclosporine and tacrolimus
